HalderVenture Limited Approves Allotment of Equity Warrants Worth ₹25 Crore
Halder Venture Limited has approved the allotment of 7,93,650 convertible equity warrants on a preferential basis to a non-promoter investor. The decision was taken at the company’s Board of Directors meeting held on July 24, 2026, as part of its capital-raising initiative.
The preferential issue will raise approximately ₹25 crore, with the proceeds expected to support the company’s business and growth plans.
Key Details of the Preferential Warrant Issue
The company has allotted convertible warrants with the following terms:
- Allottee: P.K. Bio Link Private Limited (Non-Promoter Category)
- Number of Warrants: 7,93,650
- Issue Price: ₹315 per warrant
- Face Value: ₹10 per warrant
- Securities Premium: ₹305 per warrant
- Total Issue Size: Approximately ₹25 crore
Each warrant carries the right to subscribe to one fully paid-up equity share of Halder Venture Limited having a face value of ₹10 per share, subject to the terms of the issue.
Upfront Subscription Amount Received
In accordance with SEBI regulations governing preferential issues:
- Upfront Payment Received: 25% of the total subscription amount
- Amount Received: Approximately ₹6.25 crore
The remaining 75% of the subscription amount will be payable by the warrant holder at the time of conversion into equity shares within the prescribed regulatory period.
Regulatory Approvals
The preferential allotment follows the receipt of all required regulatory and shareholder approvals.
Key approvals include:
- Shareholders’ Approval: Obtained through a Postal Ballot on April 29, 2026.
- In-Principle Approval: Received from both BSE Limited and the National Stock Exchange of India Limited (NSE) on July 9, 2026.
The allotment has also been disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Next Steps
Following the receipt of the initial subscription amount, the warrants may be converted into equity shares upon payment of the remaining consideration, in accordance with the applicable SEBI regulations and the terms of the preferential issue.
The capital infusion is expected to strengthen the company’s financial position and provide additional resources to support future business growth.